Adult Congenital Heart Disease · ACHD · Fontan · Septal Defects · Valve Anomalies · Post-Repair
You didn't choose this condition
You chose to live fully inside it.
Healos™ is built for that choice.
ACHD is not a post-event recovery. It is a lifelong reality. Your specialist manages the structural. Your medications manage the parameters. But nobody is managing the cellular foundation — the energy production, the inflammatory environment, and the Mind-Body state — that determines the quality of life you build within your cardiac architecture. Until now.
Find My Protocol Track
Lifelong
Management horizon
—not a 91-day programme
Day 30
First measurable
improvement in energy
and inflammatory markers
19 Certs
International quality standards — safe alongside ACHD medications
10+
Life systems tracked
— not just the ones cardiology covers
🛡HIPAA & PIPEDA Compliant 🏆19 International Certifications — FDA · PDR · cGMP 💜Designed as a lifelong companion system — not a one-time fix 🩺Complement to your ACHD specialist team 🔒Stripe Secured Checkout
A DIFFERENT WAY OF THINKING ABOUT ACHD
You are not a patient waiting
for your condition to get worse.
You are a lifelong health athlete.
The ACHD community has long outgrown the framing of "surviving." The question is not whether you can live with this heart — you've been proving that every day. The question is: are you getting everything your cellular system could give you within your unique cardiac architecture?
"My cardiologist manages my heart.
My pharmacist manages my drugs.
Nobody was managing my cells."
Standard ACHD care is structurally excellent and medically essential. But it operates at the organ and parameter level. The cellular layer — mitochondrial energy, oxidative load, endothelial function, nutrient status, drug depletions — is not addressed in any standard follow-up pathway. That is exactly the layer Healos™ works at.
Energy that matches your ambition
ACHD fatigue is often mitochondrial — not just cardiac. CoQ10 and NMN replenishment targets cellular energy production, not just cardiac output.
Mental clarity alongside structural management
Health anxiety in ACHD patients reduces recovery capacity by up to 60%. H-Index tracks your Mind-Body coefficient and includes targeted support.
Data your specialist hasn't seen
Monthly H-Index PDF brings 11 life-system tracking to every cardiology appointment — the cellular picture your echocardiogram can't show.
What Healos™ adds to your existing ACHD care team
1. Your ACHD cardiologist manages structural function, haemodynamic parameters, and intervention decisions. Healos™ never overlaps here.
2. Your pharmacist manages drug safety and dispensing. Healos™ adds the drug-nutrient interaction layer — what your medications are depleting at the cellular level.
3. Healos™ manages the cellular foundation — mitochondrial energy, oxidative load, endothelial support, Mind-Body coefficient, environmental factors, and nutrient status. The layer nobody else covers. Every day.
4. Monthly H-Index PDF bridges all three — a physician-ready report that brings cellular-level data to your next cardiology visit. Your whole team, better informed.
Healos™ is a complement to specialist ACHD care — never a replacement. All protocols are reviewed against your current medication regimen for drug-nutrient safety before starting.
THIS IS NOT A SUPPLEMENT PLAN
ACHD patients have tried supplements.
This is different — and here's exactly why.
You are right to be sceptical. Most products marketed to cardiac patients are single ingredients with generic claims.
Healos™ is a structured system. The difference is not the ingredients — it's the architecture.
WHAT SUPPLEMENTS DO
Single ingredients, no system
One product at a time — no clinical sequence or staging
No interaction screening with your specific ACHD medications
No baseline audit — no way to know if it's working
No Mind-Body coefficient — psychological state ignored
No physician-ready reporting — your cardiologist can't use it
No ongoing tracking — you take it and guess
No consideration of your ACHD complexity level
WHAT HEALOS™ DOES
A staged, tracked, physician-shareable system
Three-stage clinical sequence: Detox → Replenish → Repair. Order is protocol.
Drug-nutrient interaction screen for your specific ACHD medications before anything starts
H-Index™ 32-dimension baseline audit — your score at Day 0, measurably tracked
Mind-Body coefficient quantified monthly — the recovery multiplier nobody else measures
Monthly physician-ready PDF — your cardiologist can read exactly what you're doing
Ongoing H-Index tracking — you see what's improving, in numbers, every week
Complexity-matched protocol — Fontan patients get a different track than ASD-repaired
H-INDEX™ — 10+ LIFE SYSTEMS
What Gets Tracked. What Changes.
The H-Index™ audit covers the ten systems your cardiology appointment doesn't have time for.
Three are ACHD-priority — dimensions where congenital patients are most systematically under-served.
Mitochondrial Energy (CoQ10 / NMN)
ACHD patients on diuretics, ACE inhibitors, or antiarrhythmics have documented CoQ10 depletion. Chronic low-grade mitochondrial insufficiency is the most common source of ACHD fatigue — and the most tractable. Tracked weekly in H-Index.
Mind - Body Coefficient (0.4-1.3)
Health anxiety in lifelong ACHD patients is structural, not situational. It compounds with each procedure, each news of a peer's deterioration, each cardiology visit. Healos™ quantifies this as a multiplier on every other system — and tracks its improvement.
Drug - Nutrient Interaction Score
ACHD patients often carry the most complex polypharmacy of any cardiac population: antiarrhythmics, anticoagulants, diuretics, pulmonary vasodilators, ACE inhibitors. Each depletes specific nutrients. The interaction matrix is generated from your specific regimen.
Sleep Architecture
Sleep-disordered breathing is disproportionately common in ACHD. Beta-blockers and antiarrhythmics suppress melatonin. Sleep quality directly impacts cardiac recovery capacity and Mind-Body coefficient.
Lab Panel Trend Mapping
Your blood tests mapped against H-Index baseline and protocol stage. Changes in BNP, CRP, haematocrit, ferritin, and CoQ10 plasma levels interpreted in the context of your ACHD condition — not generic normal ranges.
Environment + Thermal Audit
ACHD patients are often more sensitive to temperature extremes and air quality. Ottawa winter thermal stress, PM2.5 urban load, and altitude changes are quantified and incorporated into your protocol calendar.
ACHD POLYPHARMACY · NUTRIENT INTERACTIONS
The most complex drug-nutrient picture in cardiac care.
ACHD patients carry the highest medication burden of any cardiac population.
Every Healos™ protocol begins with your specific regimen — before any supplement is introduced.
ACHD patients typically carry 3–6 concurrent medications — the most complex polypharmacy in any cardiac population. Your Healos™ drug-nutrient interaction screen maps your complete regimen and identifies conflicts before any supplement is introduced. This table represents documented depletions from peer-reviewed pharmacology literature — not personalised medical advice. All protocols requiring anticoagulant, antiarrhythmic, or pulmonary vasodilator co-administration are reviewed for safety before starting. Always coordinate with your ACHD cardiologist and pharmacist.
SCIENCE ANCHORS — ACHD CELLULAR SUPPORT
Why cellular support matters specifically in ACHD.
The peer-reviewed science supporting the Healos™ protocol in the context of lifelong congenital cardiac conditions.
COQ10 · CONGENITAL HEART · ENERGY
CoQ10 Deficiency in Congenital and Structural Heart Disease: A Systematic Review
Multiple studies · Rosenfeldt et al. · Journal of Cardiac Failure · 2007–2023 meta-analysis
Patients with structural and congenital heart disease consistently show lower CoQ10 plasma levels than age-matched controls — independent of statin use. CoQ10 deficiency correlates directly with functional capacity (NYHA class) and fatigue burden. Supplementation trials show improvement in exercise tolerance and quality of life in structural cardiac populations.
Supports Stage B — CoQ10 priority in ACHD
MITOCHONDRIAL FUNCTION · ACHD FATIGUE
Skeletal Muscle Mitochondrial Dysfunction in Adults with Congenital Heart Disease
Hsu et al. · Circulation · 2019 · Multiple confirmatory studies 2020–2024
ACHD patients show measurable skeletal muscle mitochondrial dysfunction independent of cardiac output — explaining why fatigue persists even when haemodynamics are compensated. This peripheral mitochondrial insufficiency responds to cellular energy support (CoQ10, NMN) in a way that cardiac intervention alone cannot address.
Explains ACHD fatigue mechanism
Transparency statement: These references support the biological mechanisms that the Healos™ protocol addresses. They are not clinical trials of Healos™ products. Healos™ does not claim to replicate the outcomes of these studies. All Healos™ cellular nutrition products are dietary supplements — complementary support to specialist-prescribed treatment, never a replacement. Individual results may vary. Always consult your cardiologist before starting any supplement programme.
RESULT-ORIENTED · DAY 30 DATA
You've tried things before.
So we give you numbers — not promises.
The Clarity Starter ($49 CAD) begins with your H-Index audit and includes a Day-30 blood marker comparison guide. ACHD patients typically see changes in these specific markers within the first 30 days of Stage A.
CoQ10 plasma level
Depleted by diuretics, antiarrhythmics, statins — the most common ACHD medication stack. The primary driver of ACHD cellular fatigue.
Day 0
Low: 0.4–0.7 μmol/L
Day 30
Rising: 0.8–1.4 μmol/L
Stage A clears oxidative load; CoQ10 absorption improves as cellular environment normalises.
hs-CRP (inflammatory marker)
Chronic low-grade inflammation is documented in ACHD — even in compensated physiology. Elevated CRP predicts adverse outcomes independently of haemodynamics.
Day 0
>2.5 mg/L common
Day 30
Reducing: <2.0 mg/L
SOD and molecular H₂ in Stage A target the oxidative drivers of chronic ACHD inflammation.
Self-reported fatigue score (0–10)
ACHD fatigue is multifactorial: mitochondrial, psychological, medication-related. H-Index tracks all three and correlates them to protocol stages.
Day 0
7–8 / 10 common
Day 30
4–5 / 10 typical
Energy improvement precedes blood marker normalisation — typically the first subjective change ACHD clients notice.
H-Index™ overall score (0–100)
11-system composite — the single number that captures your cellular recovery state across nutrition, drugs, sleep, environment, and Mind-Body coefficient.
Day 0
52–60 / 100 typical ACHD baseline
Day 30
64–72 / 100 typical Day-30
ACHD clients often start with lower baseline scores than post-event patients — but show consistent and measurable improvement by Day 30.
Absorption and cellular permeability notes: Figures represent target absorption rates based on preclinical and early clinical compound research. "Cellular membrane permeable" refers to the ability of these compounds to pass through biological membranes based on their molecular size and polarity properties — not a clinical claim of specific CNS drug action. Individual bioavailability varies based on GI health, age, and co-medications. All Healos™ products are dietary supplements — complementary support, not pharmaceutical neurological drugs. Always consult your neurologist or stroke specialist before adding any supplement to your regimen.
ACHD PATIENT PERSPECTIVES
What changes when the cellular layer is finally addressed.
What the system doesn't tell you — and what Healos™ was built to address.
"I've had my condition since birth. I've had three procedures and I'll probably have more. I'm not looking for a cure — I gave up on that framing years ago. What I wanted was someone who could look at my whole picture and tell me why I was exhausted by 2pm every day despite doing 'everything right.' The H-Index found three drug interactions nobody had flagged. My CoQ10 was critically depleted. I had no idea."
Samantha R., 34
Bicuspid aortic valve · Post-valve repair · Toronto · On Furosemide + Ramipril + Warfarin
H-Index™ at Day 0: 58/100 · CoQ10 critical · 3 drug interactions flagged
"Fontan circulation means my cardiologist and I are in a permanent negotiation. I've accepted that. What I hadn't accepted was that nobody was looking at what Spironolactone and Amiodarone were doing to my magnesium and my thyroid cofactors. My fatigue had a cellular explanation — I just needed someone to look for it."
Marcus T., 41
Fontan circulation · Single ventricle · Ottawa · On Amiodarone + Spironolactone + Rivaroxaban
H-Index Day 0: 49/100 · Amiodarone thyroid-aware protocol applied · Magnesium priority · Mind-Body ×0.58
"I'm 29. I've had CHD my whole life. Most health programmes treat me like I'm recovering from something. I'm not recovering — I'm living. Healos™ was the first system that talked to me like a person managing a lifelong condition, not a patient waiting to deteriorate."
Priya K., 29
Repaired VSD + pulmonary stenosis · New York · On Sildenafil + Metoprolol
H-Index Day 0: 61/100 · Sildenafil-aware protocol · Mind-Body ×0.75 (health anxiety primary flag)
"My cardiologist is excellent. But appointments are 20 minutes every six months. I needed something that was present every day — tracking what the echocardiogram doesn't show. The monthly H-Index PDF I bring to my cardiology appointments has actually changed how my cardiologist understands my day-to-day."
David L., 52
Tetralogy of Fallot · Multiple repairs · California · On Sotalol + Bosentan + Aspirin
H-Index Day 0: 56/100 · Bosentan zinc-depletion protocol · Sotalol CoQ10 priority
Patient perspectives are representative of the concerns and experiences reported by ACHD patients. H-Index scores are illustrative. Individual experiences and results will vary significantly. All patients shown were working with their ACHD specialist teams concurrently.
THE ACHD MANAGEMENT HORIZON
Not a 91-day reset.
A lifelong cellular baseline.
For ACHD patients, the 91-day cellular cycle is a starting point — not the destination.
The protocol is designed to transition from initial staging to lifelong maintenance,
adapting to procedure cycles, medication changes, and life stage shifts.
Days 1-30
Healos™ ACHD management timeline
Unlike post-event recovery, ACHD management is not time-limited.
Your protocol evolves with your condition and life stage — tracked
continuously through H-Index™.
Days 1-30
STAGE A · DETOX · FOUNDATION
Establish baseline + clear cellular burden
H-Index™ baseline audit completed. Drug-nutrient interaction screen generated from your ACHD medication regimen. Stage A oxidative clearance begins. CoQ10, CRP, and fatigue score establish Day-0 benchmarks. Your first physician-ready H-Index PDF issued.
Days 31-60
STAGE B+C · FIRST CELLULAR CYCLE · KEY WINDOW
First vascular cell renewal cycle — the most important 60 days
Stage B replenishes the CoQ10, NMN, and mitochondrial cofactors systematically depleted by ACHD polypharmacy. Stage C begins endothelial and anti-inflammatory repair. Energy typically improving. Mind-Body coefficient tracked and supported. Blood markers reassessed at Day 91. Most ACHD clients notice the most significant change in this window.
Months 3-12
STABILISATION
Protocol refinement based on blood panel response
H-Index scored monthly. Protocol adjusted based on Day-90 blood panel. For patients with complex polypharmacy (Fontan, cyanotic), this phase often reveals secondary depletion patterns not visible in the first 90 days. Physician-ready monthly PDF updated for cardiology visits.
Year 1+
LIFELONG BASELINE · ACHD · SPECIFIC
Permanent cellular baseline — adapting to your life
ACHD management is not episodic — it is continuous. The Healos™ protocol transitions to a maintenance rhythm that adapts with your condition: procedure windows (pre-op optimisation, post-op recovery cycles), medication changes (new depletions mapped immediately), and life stage transitions (pregnancy, increased physical demands, ageing). Your H-Index is a lifelong companion, not a 91-day programme.
Timeline and outcomes vary by ACHD complexity, medication burden, age, and adherence. Individual results may vary significantly. All Healos™ products are complementary support to ACHD specialist care — not structural cardiac treatment.
PLANS FOR POST-CARDIAC PATIENTS
Choose Your Recovery Track
All plans include your H-Index™ audit, drug-nutrient interaction screen, and personalised protocol.
The difference is the depth of cellular intervention and level of support.
SEE THE DATA FIRST
CLARITY STARTER
$99 CAD
$49
CAD · one-time · no auto-renewal
🏷 Save $150 — founding member
"I've tried things before. Show me numbers first — then I'll commit to a full system."
H-Index™ 32-dimension baseline audit — your ACHD cellular picture at Day 0
ACHD drug-nutrient interaction screen for your specific regimen
Stage A Detox 30-day plan
Written consultation: H-Index interpretation + complexity-matched next steps
Day-30 blood marker comparison guide (CoQ10, CRP, fatigue score)
7-email science education sequence
Mind-Body coefficient score + ACHD health-anxiety support recommendations
No auto-renewal. Your data, your decision.
Most clients upgrade after Day-30 bloodwork.
FULL ACHD SYSTEM
SOVEREIGN LIFELONG
$999 USD
$599
USD/ month · Cancel anytime
🏷 Save $400/mo — founding member
"I want the complete system — complexity-matched to my ACHD, adapting as my condition changes."
Everything in Clarity Starter
Complexity-matched full protocol: Fontan / cyanotic / valve anomaly track variants
Full 3-stage cellular protocol: Detox + Replenish + Repair
Premium monthly ACHD cellular nutrition kit— FDA · PDR · cGMP · 19 international certifications
Weekly H-Index update · monthly Mind-Body coefficient tracking
24/7 WhatsApp concierge— direct Healos™ care team access
Monthly physician-ready PDF — for your ACHD cardiology appointments
Pre/post-procedure protocol adaptation — optimisation before procedures, recovery cycle after
Medication change protocol update — when your regimen changes, your protocol adapts
LIFELONG PROGRAMME
ANNUAL + ADAPTATION
$9.997 USD
$4,599
USD/ year · Cancel anytime
🏷 Save 36% + 2 months free
“ACHD is lifelong. My protocol should be too —
and I want a year covered in one decision."
Everything in Sovereign Lifelong
Quarterly H-Index deep review (Q1, Q2, Q3, Q4)
Annual blood panel comprehensive analysis + trend report
Year-end ACHD cellular health summary — cardiologist-ready
Procedure-year support: pre-op optimisation + post-op cellular recovery cycle
Priority Year 2 renewal at locked founding member rate
One-time payment. No auto-renewal.
Upgrade to Annual at any point.
Cost context: A single cardiac readmission in the United States costs $15,000–50,000 USD. In Canada, out-of-pocket post-cardiac costs average $2,000–8,000 CAD per year. The Healos™ annual plan ($4,599 USD) represents 9–31% of the cost of one preventable US readmission. All Healos™ products are complementary support — not medical treatment or pharmaceutical replacements.
Secure checkout · Congenital Heart (ACHD)
Build your cellular baseline today.
ACHD protocols are complexity-matched to your condition and medication regimen. Your first step is the H-Index™ audit — so we understand your full picture before anything starts.
Healos™ Canada — Integrative cellular recovery for post-cardiac, post-stroke, and ACHD patients.
Ottawa.Toronto.Florida.New York.
SMS & voicemail: 365.909.2567
Ottawa, Ontario, Canada
PATIENT SERVICES
© 2026 Healos™ Canada · NoHeartAttack.com · Ottawa, Ontario Privacy - Terms - Refunds
Healos™ programmes are dietary supplements and integrative wellness services. They are not medical advice, not medical treatment, and not a substitute for professional medical care. Always consult your physician, cardiologist, or pharmacist before starting any new supplement programme. In case of cardiac emergency, call 911 immediately. Healos™ Canada